RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion

Oncology Reports

Volumn 34, Issue 6, 2015, Pages 3007-3016

  Shang, Wen Qing ^a,b   Li, Hui ^b   Liu, Li Bing ^b   Chang, Kai Kai ^b   Yu, Jia Jun ^b   Xie, Feng ^c   Li, Ming Qing ^b,c,d   Yu, Jin Jin ^a  

^a JIANGNAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH   (China)

Author keywords

Apoptosis; Cervical cancer cells; IL 8; RANK; RANKL; Viability

Indexed keywords

FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 8; KI 67 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL 2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; FASLG PROTEIN, HUMAN; NEUTRALIZING ANTIBODY; OSTEOPROTEGERIN; RECOMBINANT PROTEIN; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL LINE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIHA CELL LINE; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; UTERINE CERVIX TUMOR;

ANTIBODIES, NEUTRALIZING; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; INTERLEUKIN-8; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS C-BCL-2; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECOMBINANT PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84943754142     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4303     Document Type: Article

References (34)

1. Stewart BW and Wild CP (eds). World Cancer Report 2014. World Health Organization. Chapter 5.12. IARC Nonserial Publication, 2014.
2. Fu Z, Chen D, Cheng H and Wang F: Hypoxia-inducible factor-1α protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia. Med Sci Monit 21: 318-325, 2015.
3. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
4. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D and Galibert L: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390: 175-179, 1997.
5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, et al: The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50, 2000.
6. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, et al: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102, 2010.
7. Rossi SW, Kim MY, Leibbrandt A, Parnell SM, Jenkinson WE, Glanville SH, McConnell FM, Scott HS, Penninger JM, Jenkinson EJ, et al: RANK signals from CD4+3-inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med 204: 1267-1272, 2007.
8. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, et al: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696, 2006.
9. Hanada R, Hanada T, Sigl V, Schramek D and Penninger JM: RANKL/RANK-beyond bones. J Mol Med (Berl) 89: 647-656, 2011.
10. Cheng ML and Fong L: Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol 3: 329, 2014.
11. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P, Viñals F, et al: RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72: 2879-2888, 2012.
12. Hsu CJ, Lin TY, Kuo CC, Tsai CH, Lin MZ, Hsu HC, Fong YC and Tang CH: Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration. J Cell Biochem 111: 138-147, 2010.
13. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET and Dougall WC: RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104, 2008.
14. Chen LM, Kuo CH, Lai TY, Lin YM, Su CC, Hsu HH, Tsai FJ, Tsai CH, Huang CY and Tang CH: RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation. J Cell Biochem 112: 933-941, 2011.
15. Murdoch C and Finn A: Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032-3043, 2000.
16. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P and Bonecchi R: The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21: 27-39, 2010.
17. Vicari AP and Caux C: Chemokines in cancer. Cytokine Growth Factor Rev 13: 143-154, 2002.
18. Nickel R, Beck LA, Stellato C and Schleimer RP: Chemokines and allergic disease. J Allergy Clin Immunol 104: 723-742, 1999.
19. Liu LB, Xie F, Chang KK, Li MQ, Meng YH, Wang XH, Li H, Li DJ and Yu JJ: Hypoxia promotes the proliferation of cervical carcinoma cells through stimulating the secretion of IL-8. Int J Clin Exp Pathol 7: 575-583, 2014.
20. Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M and Zauli G: Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in Bchronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 207: 158-164, 2006.
21. Xie F, Meng YH, Liu LB, Chang KK, Li H, Li MQ and Li DJ: Cervical carcinoma cells stimulate the angiogenesis through TSLP promoting growth and activation of vascular endothelial cells. Am J Reprod Immunol 70: 69-79, 2013.
22. Chu GC and Chung LW: RANK-mediated signaling network and cancer metastasis. Cancer Metastasis Rev 33: 497-509, 2014.
23. Meng YH, Li H, Chen X, Liu LB, Shao J, Chang KK, Du MR, Jin LP, Li MQ and Li DJ: RANKL promotes the growth of decidual stromal cells in an autocrine manner via CCL2/CCR2 interaction in human early pregnancy. Placenta 34: 663-671, 2013.
24. Deivendran S, Marzook KH and Radhakrishna Pillai M: The role of inflammation in cervical cancer. Adv Exp Med Biol 816: 377-399, 2014.
25. Husseinzadeh N and Davenport SM: Role of toll-like receptors in cervical, endometrial and ovarian cancers: A review. Gynecol Oncol 135: 359-363, 2014.
26. Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M and Musiani P: Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer 75: 855-859, 1997.
27. Tang ZN, Zhang F, Tang P, Qi XW and Jiang J: Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells. Biochem Biophys Res Commun 408: 411-416, 2011.
28. Wada T, Nakashima T, Hiroshi N and Penninger JM: RANKLRANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12: 17-25, 2006.
29. Wang L, Guo H, Yang L, Dong L, Lin C, Zhang J, Lin P and Wang X: Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction. Mol Cell Biochem 379: 7-18, 2013.
30. Kim SH, Kim SH, Kim YB, Jeon YT, Lee SC and Song YS: Genistein inhibits cell growth by modulating various mitogenactivated protein kinases and AKT in cervical cancer cells. Ann NY Acad Sci 1171: 495-500, 2009.
31. Rashmi R, DeSelm C, Helms C, Bowcock A, Rogers BE, Rader JL, Grigsby PW and Schwarz JK: AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake. PLoS One 9: e92948, 2014.
32. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, et al: Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65: 11001-11009, 2005.
33. Bouganim N and Clemons MJ: Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block? Future Oncol 7: 381-383, 2011.
34. Sordillo EM and Pearse RN: RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 97 (Suppl): S802-S812, 2003.